Wen-Yue Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wen-Yue Liu has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Ming-Hua Zheng
MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
3 shared publications - Grazia Pennisi
Section of Gastroenterology and Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy
2 shared publications - Mohamed El-Kassas
Endemic Medicine Department, Faculty of Medicine Capital University (Formerly Helwan University) Cairo Egypt
2 shared publications - Ying Shang
Department of Medicine, Huddinge Karolinska Institutet Stockholm Sweden
2 shared publications - Adriaan Georgius Holleboom
Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
1 shared publication - Adrián Gadano
Hospital Italiano de Buenos Aires
1 shared publication
Latest Publications
- 24 September 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , E70-E71
Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Was not provided for this article.
- 24 September 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , E70-E71
Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Was not provided for this article.
- 14 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease, and liver biopsy remains the gold standard for diagnosis. However, a subset of patients diagnosed with MASLD by imaging paradoxically exhibit steatosis grade S0 on liver biopsy, posing a diagnostic challenge. This study investigated the outcomes and causes of steatosis 0. METHODS: Steatosis 0 was defined as imaging-detected MASLD with a biopsy-defined steatosis grade S0. We used global cohorts to evaluate outcomes, histologic progression by paired biopsies, and possible causes. The cause analysis included MRI-proton density fat fraction (MRI-PDFF) for fat distribution, pathologist consistency testing, and comparison of serial biopsy sections. RESULTS: In a follow-up cohort of 3,273 biopsy individuals from 16 centers, 123 (3.8%) exhibited steatosis 0. Of these, 29.3% of them had advanced fibrosis (burnt-out MASLD) and demonstrated a risk of liver-related events, whereas those without advanced fibrosis had no such events. In the paired-biopsy cohort of 1,865 patients, 74 (4.0%) individuals initially showed steatosis grade S0; among them, 93.2% retained no or mild steatosis on follow-up biopsy. MRI-PDFF assessments in 42 MASLD patients revealed heterogeneous hepatic fat distribution, with some segments showing steatosis grade S0 despite elevated average liver fat. Interpathologist variability and discrepancies across consecutive biopsy sections contributed to misclassification of steatosis grade. DISCUSSION: Steatosis 0 represents a potential diagnostic gray zone in MASLD. It may be caused by burnt-out MASLD, uneven liver fat distribution, or variability in pathological assessment. Understanding the causes and implications of steatosis 0 is critical for diagnosis and management.
- 14 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease, and liver biopsy remains the gold standard for diagnosis. However, a subset of patients diagnosed with MASLD by imaging paradoxically exhibit steatosis grade S0 on liver biopsy, posing a diagnostic challenge. This study investigated the outcomes and causes of steatosis 0. METHODS: Steatosis 0 was defined as imaging-detected MASLD with a biopsy-defined steatosis grade S0. We used global cohorts to evaluate outcomes, histologic progression by paired biopsies, and possible causes. The cause analysis included MRI-proton density fat fraction (MRI-PDFF) for fat distribution, pathologist consistency testing, and comparison of serial biopsy sections. RESULTS: In a follow-up cohort of 3,273 biopsy individuals from 16 centers, 123 (3.8%) exhibited steatosis 0. Of these, 29.3% of them had advanced fibrosis (burnt-out MASLD) and demonstrated a risk of liver-related events, whereas those without advanced fibrosis had no such events. In the paired-biopsy cohort of 1,865 patients, 74 (4.0%) individuals initially showed steatosis grade S0; among them, 93.2% retained no or mild steatosis on follow-up biopsy. MRI-PDFF assessments in 42 MASLD patients revealed heterogeneous hepatic fat distribution, with some segments showing steatosis grade S0 despite elevated average liver fat. Interpathologist variability and discrepancies across consecutive biopsy sections contributed to misclassification of steatosis grade. DISCUSSION: Steatosis 0 represents a potential diagnostic gray zone in MASLD. It may be caused by burnt-out MASLD, uneven liver fat distribution, or variability in pathological assessment. Understanding the causes and implications of steatosis 0 is critical for diagnosis and management.
- 3 July 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 233
Automated Machine Learning Model for Non-Alcoholic Fatty Liver Disease Prediction and External Cohort Validation
Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder associated with obesity, insulin resistance, and metabolic syndrome, often going undiagnosed until advanced stages. Traditional diagnostic methods, including imaging and liver biopsy, have limitations in early detection. There is a need for an efficient, non-invasive tool for early NAFLD screening. Using automated machine learning (AutoML) technology, a diagnostic model for NAFLD was developed leveraging a large dataset from NHANES (n = 2677). Additionally, an independent external validation cohort (n = 200) was employed to assess the external validity and performance of the model. For selection of promising clinical features, A two-stage feature selection method was applied, combining LASSO regression with ChatGPT-4-based intelligent analysis. Subsequently, the AutoML process, which integrated multiple machine learning algorithms, was performed for model training and validation. The model's performance was evaluated using ROC curves, F1 scores, and SHapley additive explanation (SHAP) analysis. The GBM model achieved an AUC of 0.843 in the training set, 0.851 in the testing set, and 0.945 in the external validation set, demonstrating high diagnostic accuracy across different datasets. Key predictors, including BMI, triglycerides, and GGT, were identified as significant contributors to the model's predictions. SHAP analysis further confirmed the importance of these variables in predicting NAFLD. The AutoML-driven diagnostic model for NAFLD demonstrated significantly improved early-detection performance, offering a reliable, non-invasive, and efficient alternative to conventional diagnostic methods. This method holds great potential for broader clinical application in NAFLD, diminishing dependence on expert knowledge while improving diagnostic precision.
- 3 July 2026
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 233
Automated Machine Learning Model for Non-Alcoholic Fatty Liver Disease Prediction and External Cohort Validation
Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder associated with obesity, insulin resistance, and metabolic syndrome, often going undiagnosed until advanced stages. Traditional diagnostic methods, including imaging and liver biopsy, have limitations in early detection. There is a need for an efficient, non-invasive tool for early NAFLD screening. Using automated machine learning (AutoML) technology, a diagnostic model for NAFLD was developed leveraging a large dataset from NHANES (n = 2677). Additionally, an independent external validation cohort (n = 200) was employed to assess the external validity and performance of the model. For selection of promising clinical features, A two-stage feature selection method was applied, combining LASSO regression with ChatGPT-4-based intelligent analysis. Subsequently, the AutoML process, which integrated multiple machine learning algorithms, was performed for model training and validation. The model's performance was evaluated using ROC curves, F1 scores, and SHapley additive explanation (SHAP) analysis. The GBM model achieved an AUC of 0.843 in the training set, 0.851 in the testing set, and 0.945 in the external validation set, demonstrating high diagnostic accuracy across different datasets. Key predictors, including BMI, triglycerides, and GGT, were identified as significant contributors to the model's predictions. SHAP analysis further confirmed the importance of these variables in predicting NAFLD. The AutoML-driven diagnostic model for NAFLD demonstrated significantly improved early-detection performance, offering a reliable, non-invasive, and efficient alternative to conventional diagnostic methods. This method holds great potential for broader clinical application in NAFLD, diminishing dependence on expert knowledge while improving diagnostic precision.
- 16 May 2024
- Published by Elsevier in Metabolism
- Vol. 156, 155935
Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world
- 16 May 2024
- Published by Elsevier in Metabolism
- Vol. 156, 155935
Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world
- Open Access
- 8 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (15)
SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface
Genetic polymorphisms are associated with the development of nonalcoholic fatty liver disease (NAFLD). Semaphorin7a ( Sema7a ) deficiency in mouse peritoneal macrophages reduces fatty acid (FA) oxidation. Here, we identified 17 individuals with SEMA7A heterozygous mutations in 470 patients with biopsy-proven NAFLD. SEMA7A heterozygous mutations increased susceptibility to NAFLD, steatosis severity, and NAFLD activity scores in humans and mice. The Sema7a R145W mutation (equivalent to human SEMA7A R148W ) significantly induced small lipid droplet accumulation in mouse livers compared with WT mouse livers. Mechanistically, the Sema7a R145W mutation increased N-glycosylated Sema7a and its receptor integrin β1 proteins in the cell membranes of hepatocytes. Furthermore, Sema7a R145W mutation enhanced its protein interaction with integrin β1 and PKC-α and increased PKC-α phosphorylation, which were both abrogated by integrin β1 silencing. Induction of PKC α _WT, but not PKC α _dominant negative, overexpression induced transcriptional factors Srebp1, Chrebp, and Lxr expression and their downstream Acc1, Fasn, and Cd36 expression in primary mouse hepatocytes. Collectively, our findings demonstrate that the SEMA7A R148W mutation is a potentially new strong genetic determinant of NAFLD and promotes intrahepatic lipid accumulation and NAFLD in mice by enhancing PKC-α–stimulated FA and triglyceride synthesis and FA uptake. The inhibition of hepatic PKC-α signaling may lead to novel NAFLD therapies.
- 8 August 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (15)
Open AccessSEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface
Genetic polymorphisms are associated with the development of nonalcoholic fatty liver disease (NAFLD). Semaphorin7a ( Sema7a ) deficiency in mouse peritoneal macrophages reduces fatty acid (FA) oxidation. Here, we identified 17 individuals with SEMA7A heterozygous mutations in 470 patients with biopsy-proven NAFLD. SEMA7A heterozygous mutations increased susceptibility to NAFLD, steatosis severity, and NAFLD activity scores in humans and mice. The Sema7a R145W mutation (equivalent to human SEMA7A R148W ) significantly induced small lipid droplet accumulation in mouse livers compared with WT mouse livers. Mechanistically, the Sema7a R145W mutation increased N-glycosylated Sema7a and its receptor integrin β1 proteins in the cell membranes of hepatocytes. Furthermore, Sema7a R145W mutation enhanced its protein interaction with integrin β1 and PKC-α and increased PKC-α phosphorylation, which were both abrogated by integrin β1 silencing. Induction of PKC α _WT, but not PKC α _dominant negative, overexpression induced transcriptional factors Srebp1, Chrebp, and Lxr expression and their downstream Acc1, Fasn, and Cd36 expression in primary mouse hepatocytes. Collectively, our findings demonstrate that the SEMA7A R148W mutation is a potentially new strong genetic determinant of NAFLD and promotes intrahepatic lipid accumulation and NAFLD in mice by enhancing PKC-α–stimulated FA and triglyceride synthesis and FA uptake. The inhibition of hepatic PKC-α signaling may lead to novel NAFLD therapies.